MarketBeat
07 Nov 2026, 13:30 UTC · 52m ago
What Guardian Pharmacy Services (GRDN) Said on Its Q3 Earnings Call
Impact · against what's priced in
Guardian Pharmacy Services (GRDN) is seeing strong operating leverage and volume growth, leading to an upward revision in FY2026 EBITDA and revenue guidance. While short-term profit momentum is high, management's warning that future gains will not match this year's magnitude suggests a ceiling on margin expansion heading into 2027.
- GRDN+0.50
No priced-in read yet
- In context
The company raised its FY2026 adjusted EBITDA guidance midpoint by $4.5M to a range of $136M-$138M, driven by a 24% YoY increase in Q3 adjusted EBITDA and a 10% rise in prescription volumes.
Read from the article alone
